Completed PHASE4 INTERVENTIONAL 2-arm NCT05491356

Use of Tissue Plasminogen Activator in the Clearance of Chronic Subdural Hematomas

The Utility of Intra-Catheter Fibrinolytics in Draining Chronic Subdural Hematomas: A Randomized Controlled Trial Pilot Study

Sponsor: Hamilton Health Sciences Corporation

Conditions Fibrinolytic; Hemorrhage Hematoma, Subdural

Interventions Placebo Tissue Plasminogen Activator

Updated 9 times since 2022 Last updated: Mar 10, 2026 Started: May 11, 2023 Primary completion: Mar 30, 2024 Completion: May 30, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Fibrinolytic; Hemorrhage and Hematoma, Subdural and is currently completed. Hamilton Health Sciences Corporation leads this study, which shows 9 recorded versions since 2023 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

9 versions recorded

Mar 2026 — Present [monthly]

Completed PHASE4
Jun 2025 — Mar 2026 [monthly]

Completed PHASE4
Apr 2025 — Jun 2025 [monthly]

Completed PHASE4

Status: Recruiting → Completed
Sep 2024 — Apr 2025 [monthly]

Recruiting PHASE4
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE4

▶ Show 4 earlier versions

Apr 2024 — Jul 2024 [monthly]

Recruiting PHASE4
Oct 2023 — Apr 2024 [monthly]

Recruiting PHASE4

Status: Not Yet Recruiting → Recruiting
Jan 2023 — Oct 2023 [monthly]

Not Yet Recruiting PHASE4
Sep 2022 — Jan 2023 [monthly]

Not Yet Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hamilton Health Sciences Corporation

Data source: Hamilton Health Sciences Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hamilton, Canada